Monomeric DR2/MOG-35-55 recombinant TCR ligand treats relapses of experimental encephalomyelitis in DR2 transgenic mice

Monomeric DR2/MOG-35-55 recombinant TCR ligand treats relapses of experimental encephalomyelitis in DR2 transgenic mice

Treatment of human autoimmune diseases such as multiple sclerosis (MS) will likely require agents that can prevent or reverse the inflammatory process that results in clinical relapses and disease progression. We evaluated the ability of a newly designed monomeric recombinant TCR ligand (RTL342M) co...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 123(2007), 1 vom: 01. Apr., Seite 95-104
1. Verfasser: Link, Jason M (VerfasserIn)
Weitere Verfasser: Rich, Cathleen M, Korat, Maya, Burrows, Gregory G, Offner, Halina, Vandenbark, Arthur A
Format: Aufsatz
Sprache:English
Veröffentlicht: 2007
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Glycoproteins HLA-DR2 Antigen Ligands Myelin-Oligodendrocyte Glycoprotein Peptide Fragments Receptors, Antigen, T-Cell mehr... Recombinant Proteins myelin oligodendrocyte glycoprotein (35-55)